UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 202

Sortiert nach

The chronic myeloid leukemia stem cell: stemming the tide of persistence

Blood, 2017-03, Vol.129 (12), p.1595-1606

2017

Volltextzugriff (PDF)

Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells

Nature medicine, 2017-10, Vol.23 (10), p.1234-1240

2017

Volltextzugriff (PDF)

Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with Imatinib

Cancer cell, 2012-02, Vol.21 (2), p.266-281

2012

Volltextzugriff (PDF)

Altered Microenvironmental Regulation of Leukemic and Normal Stem Cells in Chronic Myelogenous Leukemia

Cancer cell, 2012-04, Vol.21 (4), p.577-592

2012

Volltextzugriff (PDF)

Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor–treated CML stem cells

Blood, 2016-12, Vol.128 (23), p.2671-2682

2016

Volltextzugriff (PDF)

Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia

Blood, 2014-06, Vol.123 (25), p.3951-3962

2014

Volltextzugriff (PDF)

Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells

Nature (London), 2016-06, Vol.534 (7607), p.341-346

2016

Volltextzugriff (PDF)

Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition

JNCI : Journal of the National Cancer Institute, 2018-05, Vol.110 (5), p.467-478

2018

Volltextzugriff (PDF)

CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy

Leukemia, 2020-06, Vol.34 (6), p.1613-1625

2020

Volltextzugriff (PDF)

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells

The Journal of clinical investigation, 2013-10, Vol.123 (10), p.4144-4157

2013

Volltextzugriff (PDF)

CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression

Blood, 2017-01, Vol.129 (2), p.199-208

2017

Volltextzugriff (PDF)

Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition

Cancer discovery, 2016-11, Vol.6 (11), p.1248-1257

2016

Volltextzugriff (PDF)

Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells

Blood, 2013-05, Vol.121 (20), p.4175-4183

2013

Volltextzugriff (PDF)

Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606

Blood, 2008-02, Vol.111 (4), p.2329-2338

2008

Volltextzugriff (PDF)

The Antiproliferative Activity of Kinase Inhibitors in Chronic Myeloid Leukemia Cells Is Mediated by FOXO Transcription Factors

Stem cells (Dayton, Ohio), 2014-09, Vol.32 (9), p.2324-2337

2014

Volltextzugriff (PDF)

hsa-mir183/EGR1–mediated regulation of E2F1 is required for CML stem/progenitor cell survival

Blood, 2018-04, Vol.131 (14), p.1532-1544

2018

Volltextzugriff (PDF)

Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML

Clinical cancer research, 2016-04, Vol.22 (8), p.2051-2061

2016

Volltextzugriff (PDF)

Assembling defenses against therapy-resistant leukemic stem cells: Bcl6 joins the ranks

The Journal of experimental medicine, 2011-10, Vol.208 (11), p.2155-2158

2011

Volltextzugriff (PDF)

Lineage tracing of Pf4-Cre marks hematopoietic stem cells and their progeny

PloS one, 2012-12, Vol.7 (12), p.e51361-e51361

2012

Volltextzugriff (PDF)

Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1―BCR-ABL―JAK2 Complex

JNCI : Journal of the National Cancer Institute, 2013-03, Vol.105 (6), p.405-423

2013

Volltextzugriff (PDF)

Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells

Cancer research (Chicago, Ill.), 2008-12, Vol.68 (23), p.9624-9633

2008

Volltextzugriff (PDF)

Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate

Blood, 2006-08, Vol.108 (4), p.1370-1373

2006

Volltextzugriff (PDF)

Autophagy in blood cancers: biological role and therapeutic implications

Haematologica (Roma), 2013-09, Vol.98 (9), p.1335-1343

2013

Volltextzugriff (PDF)

1 – 25 von 202

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(197)
Mit Volltextzugriff
(185)

Publikationsform

Artikel
(201)
Buchkapitel
(1)

Sprache

Englisch
(202)
Japanisch
(34)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The chronic myeloid leukemia stem cell: stemming the tide of persistence

Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells

Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with Imatinib

Altered Microenvironmental Regulation of Leukemic and Normal Stem Cells in Chronic Myelogenous Leukemia

Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor–treated CML stem cells

Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia

Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells

Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition

Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia

CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells

CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression

Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition

Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells

Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606

The Antiproliferative Activity of Kinase Inhibitors in Chronic Myeloid Leukemia Cells Is Mediated by FOXO Transcription Factors

Rac2-MRC-cIII–generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors

hsa-mir183/EGR1–mediated regulation of E2F1 is required for CML stem/progenitor cell survival

Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML

Assembling defenses against therapy-resistant leukemic stem cells: Bcl6 joins the ranks

Lineage tracing of Pf4-Cre marks hematopoietic stem cells and their progeny

Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1―BCR-ABL―JAK2 Complex

Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells

Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate

Autophagy in blood cancers: biological role and therapeutic implications

Suchergebnisse filtern